ANIP
ANI Pharmaceuticals, Inc.
$82.72
Platform & Compounding FCF
85%
Two-stage FCF DCF
Strong
·
Conviction
Undervalued
Trading 67.4% below fair value
You pay
$82.72
Bear
$138.10
Fair
$253.46
Bull
$398.34
Bear
$138.10
+67.0%
12% stage 1 growth, 11% discount
Fair
$253.46
+206.4%
20% stage 1 growth, 11% discount
Bull
$398.34
+381.6%
26% stage 1 growth, 11% discount
Key Value Driver
FCF growth rate (20% base case)
Terminal Value % of EV
46%
Implied Market Multiple
13.4x
Summary
Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $124.00 from 10 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $253.46 per share.
Warnings
Stock-based employee pay equals 48% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.
Wall Street's average price target is $124.00 (from 10 analysts). Our estimate is 131% above the consensus -- consider that gap carefully.
Key Risks
- P/E alone misleads — earnings depressed by growth investment
- Cyclical or commodity businesses may be misclassified as platforms
- Terminal value dominance suggests sensitivity to long-run assumptions